(Q36806140)

16 August 2017

1 reference

title

Managing oral chemotherapy: the healthcare practitioner's role (English)

1 reference

16 August 2017

1 reference

Carol S Viele

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

American Journal of Health-System Pharmacy

16 August 2017

published in

1 reference

16 August 2017

volume

64

1 reference

16 August 2017

issue

9 Suppl 5

1 reference

16 August 2017

page(s)

S25-32

1 reference

Adherence to therapy with oral antineoplastic agents

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Symptoms associated with tamoxifen treatment in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Medication management capacity in highly functioning community-living older adults: detection of early deficits.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Individualized drug use assessment in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Side effects of adjuvant treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Tamoxifen in the treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

31 March 2020

Severe acneiform rash

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070037

31 March 2020

Identifiers

DOI

10.2146/AJHP070037

1 reference

16 August 2017

1 reference